Premium
Effects of nedocromil sodium (Tilade®) on the activation of human eosinophils and neutrophils and the release of histamine from mast cells
Author(s) -
Moqbel R.,
Cromwell O.,
Walsh G. M.,
Wardlaw A. J.,
Kurlak L.,
Kay A. B.
Publication year - 1988
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.1988.tb00899.x
Subject(s) - nedocromil sodium , nedocromil , histamine , eosinophil , chemistry , immunoglobulin e , immunology , pharmacology , mast cell , in vitro , medicine , biochemistry , antibody , lung , asthma , respiratory disease , pathology , alternative medicine , placebo
The ability of nedocromil sodium, a new anti‐inflammatory agent for the treatment of asthma, to inhibit activation of human eosinophils and neutrophils in vitro , has been studied using an adherence reaction (the “rosette” technique) as well as a cytotoxicity assay. We have also investigated the capacity of nedocromil sodium to inhibit IgE‐ dependent histamine release from human lung mast cells. The drug was a potent inhibitor (IC50 approx 5 × 10 ‐9 M) of fMLP‐induced enhancement of eosinophil and neutrophil complement (C3b) and IgG (Fc) rosettes. There was also a comparable inhibition of enhancement, by fMLP, of eosinophil and neutrophil cytotoxicity (for complement‐coated schistosomula of Schistosoma mansoni). Although nedocromil sodium also inhibited histamine release from human lung mast cells in a dose‐dependent fashion its activity was relatively weak (IC 30 5 × 10 ‐6 M) compared to its effect on granulocytes. These experiments support the view that the principal mode of action of nedocromil sodium is its capacity to inhibit the activation of inflammatory cells.